CeriBell (NASDAQ:CBLL) Reaches New 52-Week Low - Here's Why

CeriBell (NASDAQ:CBLL - Get Free Report)'s share price reached a new 52-week low on Monday . The company traded as low as $20.06 and last traded at $20.13, with a volume of 13957 shares trading hands. The stock had previously closed at $20.93.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of research reports. Canaccord Genuity Group began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a "buy" rating and a $30.00 price target on the stock. Bank of America started coverage on CeriBell in a research note on Tuesday, November 5th. They issued a "buy" rating and a $32.00 target price on the stock. Canaccord Genuity Group lifted their price objective on CeriBell from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Monday, December 9th. William Blair began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an "outperform" rating on the stock. Finally, TD Cowen boosted their price target on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has a consensus rating of "Buy" and a consensus target price of $32.60.

CeriBell Stock Down 0.4 %

The business's fifty day moving average price is $27.05.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. Analysts predict that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.